Valley Health Systems INC
Valley Health Systems INC was paid $7.02M by Medicaid between Jan 2018 and Dec 2024, across 105 billing codes. Its largest line is 87651, Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe — 12% of everything it billed.
HUNTINGTON, WV 25702
Next to other Clinical Medical Laboratory providers in West Virginia
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Paid by month
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 60,415 | $995K | |
| 2019 | 47,780 | $650K | |
| 2020 | 51,056 | $704K | |
| 2021 | 62,193 | $447K | |
| 2022 | 76,129 | $584K | |
| 2023 | 189,423 | $1.62M | |
| 2024incomplete | 154,852 | $2.02M |
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 12% | 34,525 | 28,826 | $819K |
| 87428 | 7.9% | 22,531 | 19,134 | $558K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 7.6% | 8,880 | 7,911 | $531K |
| 80050 | General health panel | 7.1% | 14,652 | 12,840 | $501K |
| 36415 | Collection of venous blood by venipuncture | 6.7% | 105,887 | 87,206 | $473K |
| 80053 | Comprehensive metabolic panel | 4.3% | 43,562 | 37,530 | $299K |
| 80061 | Lipid panel | 4.0% | 33,223 | 28,695 | $283K |
| 87631 | 3.9% | 3,359 | 2,891 | $276K | |
| 84443 | Thyroid stimulating hormone (TSH) | 3.0% | 22,506 | 19,555 | $211K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 3.0% | 37,435 | 32,634 | $211K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 2.8% | 11,670 | 9,914 | $194K |
| 87800 | 2.5% | 5,738 | 4,992 | $178K |
93 more codes
| 83036 | Hemoglobin; glycosylated (A1C) | 2.5% | 27,417 | $174K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 2.3% | 7,219 | $162K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 2.3% | 7,212 | $161K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.8% | 3,560 | $124K |
| 81003 | 1.7% | 55,757 | $121K | |
| 86780 | 1.6% | 10,277 | $116K | |
| 81025 | 1.5% | 18,235 | $109K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 1.5% | 595 | $108K |
| 86803 | 1.5% | 8,925 | $106K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 1.3% | 5,315 | $92K |
| 87340 | 1.2% | 8,446 | $87K | |
| 87653 | 1.1% | 2,985 | $76K | |
| 84439 | 1.0% | 8,966 | $72K | |
| 80074 | <1% | 1,675 | $63K | |
| 82607 | <1% | 5,941 | $60K | |
| 83655 | <1% | 6,319 | $58K | |
| 87807 | <1% | 5,433 | $52K | |
| 86762 | <1% | 4,207 | $47K | |
| 82043 | <1% | 6,920 | $35K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 5,502 | $32K |
| 82570 | <1% | 7,026 | $32K | |
| 86709 | <1% | 1,476 | $31K | |
| 84702 | <1% | 2,512 | $31K | |
| 85027 | <1% | 8,034 | $29K | |
| 80305 | <1% | 3,212 | $27K | |
| 83550 | <1% | 4,141 | $26K | |
| 82728 | <1% | 2,831 | $26K | |
| 83540 | <1% | 4,629 | $24K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 740 | $23K |
| 87486 | <1% | 728 | $22K | |
| 84153 | <1% | 1,816 | $22K | |
| 87581 | <1% | 728 | $22K | |
| 83735 | <1% | 3,753 | $19K | |
| G0433 | Infectious agent antibody detection by enzyme-linked immunosorbent assay (elisa) technique, hiv-1 and/or hiv-2, screening | <1% | 2,692 | $18K |
| 85018 | <1% | 8,548 | $18K | |
| 87081 | <1% | 2,981 | $17K | |
| G0435 | Infectious agent antibody detection by rapid antibody test, hiv-1 and/or hiv-2, screening | <1% | 1,849 | $17K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 486 | $14K |
| 84146 | <1% | 914 | $14K | |
| 82950 | <1% | 3,423 | $14K | |
| 87660 | <1% | 907 | $12K | |
| 87480 | <1% | 884 | $12K | |
| 87510 | <1% | 884 | $11K | |
| 87634 | <1% | 242 | $11K | |
| 83001 | <1% | 892 | $10K | |
| 36416 | <1% | 10,305 | $10K | |
| 82746 | <1% | 915 | $9K | |
| 82274 | <1% | 537 | $9K | |
| 85610 | <1% | 3,054 | $8K | |
| 83690 | <1% | 1,341 | $7K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 207 | $7K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 509 | $7K |
| 86777 | <1% | 519 | $6K | |
| 85652 | <1% | 1,695 | $6K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,181 | $6K |
| 83002 | <1% | 442 | $5K | |
| 82150 | <1% | 1,140 | $5K | |
| 84550 | <1% | 1,165 | $5K | |
| 84436 | <1% | 955 | $4K | |
| 86430 | <1% | 553 | $4K | |
| 86706 | <1% | 415 | $3K | |
| 80076 | <1% | 349 | $3K | |
| 82947 | <1% | 862 | $3K | |
| 84479 | <1% | 673 | $2K | |
| 82951 | <1% | 282 | $2K | |
| 84460 | <1% | 199 | $2K | |
| 86708 | <1% | 93 | $2K | |
| 86580 | <1% | 390 | $1K | |
| 84156 | <1% | 538 | $1K | |
| 80164 | <1% | 70 | $1K | |
| 86318 | <1% | 88 | $1K | |
| 86308 | <1% | 355 | $1K | |
| 81001 | <1% | 199 | $1K | |
| 87529 | <1% | 49 | $1K | |
| 84450 | <1% | 117 | $967.04 | |
| 84703 | <1% | 113 | $847.45 | |
| 82977 | <1% | 199 | $807.20 | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 78 | $772.84 |
| 82952 | <1% | 226 | $583.33 | |
| 87186 | <1% | 134 | $499.58 | |
| 86703 | <1% | 56 | $408.63 | |
| 86850 | <1% | 76 | $345.44 | |
| 88720 | <1% | 72 | $310.23 | |
| 82550 | <1% | 13 | $267.77 | |
| 84132 | <1% | 29 | $183.21 | |
| G0328 | Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous | <1% | 127 | $134.98 |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 18 | $121.06 |
| 86900 | <1% | 76 | $110.04 | |
| 86901 | <1% | 72 | $92.83 | |
| 84100 | <1% | 29 | $44.98 | |
| 80069 | <1% | 14 | $41.63 | |
| 3044F | <1% | 17 | $0.02 | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | 0% | 100 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
Who's on the registration
| Provider | Location | Paid |
|---|---|---|
| Valley Health Systems INC | Huntington, WV | $17.20M |
| Valley Health Systems, INC | Wayne, WV | $14.08M |
| Valley Health Systems INC | Huntington, WV | $13.47M |
| Valley Health Systems INC | Huntington, WV | $13.19M |
| Valley Health Systems, INC. | Milton, WV | $11.01M |
| Valley Health Systems INC | Huntington, WV | $10.23M |
| Valley Health Systems INC | Huntington, WV | $10.10M |
| Valley Health Systems INC | Fort Gay, WV | $8.84M |
| Valley Health Systems INC | Hurricane, WV | $8.59M |
| Valley Health Systems, INC | Charleston, WV | $7.17M |
| Valley Health Systems INC | Coal Grove, OH | $6.42M |
| Valley Health Systems, INC. | Scott Depot, WV | $6.26M |
| Valley Health Systems INC | Huntington, WV | $4.93M |
| Valley Health Systems INC | Point Pleasant, WV | $3.40M |
| Valley Health Systems INC | Harts, WV | $2.71M |
| Valley Health Systems, INC. | Barboursville, WV | $2.70M |
| Valley Health Systems, INC. | Huntington, WV | $1.81M |
| Valley Health Systems, INC. | Huntington, WV | $1.40M |
| Valley Health Systems, INC | Huntington, WV | $1.22M |
| Valley Health Systems INC | Kermit, WV | $1.11M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.